$30.0 million upfront with up to an additional $48.0 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants for cashOffering led by Nantahala Capital, with participation of healthcare-dedicated funds, including Broadfin Holdings, and participation from existing shareholder, Glen Taylor, and members of the Company's board of directors and managementNet proceeds extend anticipated cash runway into second half of 2027, beyond expected PMA submission; if milestone- ...

Core Viewpoint - Envoy Medical, a hearing health company, is set to participate in the Small Cap Growth Virtual Investor Conference on February 5, 2026, highlighting its commitment to innovation in hearing solutions [1]. Group 1: Company Overview - Envoy Medical (NASDAQ: COCH) specializes in innovative technologies for hearing loss, offering fully implanted devices such as the Esteem® active middle ear implant, available in the U.S. since 2010, and the investigational Acclaim® cochlear implant [2]. Group 2: Event Details - The Small Cap Growth Virtual Investor Conference will take place on February 5, 2026, at 10:00 A.M. ET, featuring a presentation followed by a real-time Q&A session for investors [1]. - A recording of the event will be accessible on Envoy's Investor Relations website for those unable to attend the live session [1].

Core Insights - Envoy Medical experienced a transformational third quarter in 2025, significantly improving its financial position by eliminating $32 million in debt and strengthening its balance sheet [2][5][6] - The company received FDA approval to expand its pivotal clinical trial to the final stage, which is expected to enhance its market position in fully implanted hearing solutions [2][8] - Envoy Medical's net revenue for the third quarter was $42 thousand, a decrease from $56 thousand in the same period of 2024 [5][17] Financial Highlights - Research and Development (R&D) expenses decreased by $57 thousand to $2.7 million compared to the same quarter in 2024, as the company transitioned from development to clinical trial phases [5][17] - General and administrative expenses increased by $752 thousand, primarily due to public company costs and expenses related to a September 2025 offering [5][17] - As of September 30, 2025, the company had approximately $3.556 million in cash, down from $5.483 million at the end of 2024 [6][15] Operational Developments - The company continued to receive additional global patents in the U.S., Europe, and Australia, reinforcing its position as a market leader in fully implanted hearing solutions [2][7] - The Acclaim Cochlear Implant, an investigational device, is designed to address severe to profound sensorineural hearing loss and has received Breakthrough Device Designation from the FDA [8][9] Market Position - Envoy Medical aims to capitalize on its first-mover advantage in the fully implanted hearing solutions market, with ongoing interest in its cochlear implant trial [2][8] - The company is dedicated to advancing hearing technology to improve access and quality of life for individuals with hearing loss [7][8]

Core Insights - Envoy Medical has enrolled the first three patients in the final stage of the pivotal clinical trial for the Acclaim® cochlear implant, indicating strong market interest and potential for commercialization [1][3][4] Company Overview - Envoy Medical, Inc. is a hearing health company focused on innovative technologies for hearing loss, including the fully implanted Acclaim® cochlear implant and the Esteem® active middle ear implant [5][6] - The Acclaim cochlear implant is designed to operate without external components, utilizing a novel sensor to capture sound, which differentiates it from traditional cochlear implants [2][6] Clinical Trial Progress - The final stage of the clinical trial will involve a total of 46 patients, with 43 spots remaining after the initial three enrollments [3] - The trial is being conducted at seven investigational sites across the United States, with additional surgeries already scheduled and many potential participants in the screening process [3][4] Market Demand - There is significant demand for the fully implanted cochlear device, as indicated by the rapid patient enrollment and interest from individuals with severe hearing loss [3][4] - The CEO of Envoy Medical emphasized the urgency to meet patient needs and the strong product-market fit, which could lead to faster FDA submission and commercialization [3][4] Regulatory Status - The Acclaim cochlear implant received Breakthrough Device Designation from the FDA in 2019 and is currently under investigation as part of a pivotal clinical trial [4][7]

Core Insights - Envoy Medical has secured three new patents in the U.S., Australia, and Hong Kong, enhancing its leadership in fully implantable hearing technology [2][3][6] - The patents are aimed at advancing next-generation cochlear implant solutions, providing patients with a discreet and continuous hearing experience [2][3] Patent Details - U.S. Patent No. 12,390,634 relates to a fully implantable modular cochlear implant system that includes a signal processor and an implantable battery or communication module [3] - Australian Patent No. 2022254630 focuses on electrode impedance diagnostics in cochlear implant systems, determining stimulation parameters based on impedance [3] - Hong Kong Patent No. 40101898 pertains to cochlear implant stimulation calibration, adjusting current flow based on testing circuit outputs [3] Company Vision and Strategy - The CEO of Envoy Medical, Brent Lucas, emphasized that the new patents are critical for redefining hearing restoration solutions and expanding the company's global patent portfolio [3][6] - The company aims to eliminate daily limitations faced by millions with hearing loss through innovative, fully implantable solutions [3][6] Product Overview - Envoy Medical's Acclaim Cochlear Implant is designed for severe to profound sensorineural hearing loss and is the first fully implanted cochlear implant [8] - The Esteem fully implanted active middle ear implant is the only FDA-approved device of its kind, providing 24/7 hearing capability without external components [9]

Company Overview - Envoy Medical, Inc. is a hearing health company focused on fully implanted hearing devices that utilize the ear's natural anatomy [6] - The company has developed unique devices such as the Esteem® active middle ear implant and the investigational Acclaim® cochlear implant [6][8] Recent Developments - Brent Lucas, CEO of Envoy Medical, will present at the Life Sciences Virtual Investor Forum on June 12, 2025, allowing real-time interaction with investors [1][2] - The Acclaim CI has received Breakthrough Device Designation from the FDA in 2019 and is designed for severe to profound sensorineural hearing loss [8] Clinical Trials - Envoy Medical's pivotal clinical trial for the Acclaim CI is on track after the first month follow-up, with optimism about progressing to the final stage of the trial [9] Product Features - The Acclaim CI is a first-of-its-kind device that captures sound using the ear's natural anatomy and is powered by a rechargeable battery [7] - The Esteem FI-AMEI is the only FDA-approved fully implanted hearing device for adults with moderate to severe sensorineural hearing loss, offering continuous hearing without external components [11]